HASBROUCK HEIGHTS, N.J.--(BUSINESS WIRE)--Nymox Pharmaceutical Corporation (NASDAQ: NYMX) announced today completion of a large new 2 year follow-up study of NX-1207 for benign prostatic hyperplasia (BPH). The study evaluated symptomatic progress of over one hundred subjects involved in the Company’s Phase 2 U.S. clinical trial initiated in 2005. Individuals in the study were assessed 2 years after NX-1207 treatment for symptomatic improvement, treatment outcomes, and durability of efficacy. This is the largest cohort of patients treated with NX-1207 followed for as long as 2 years thus far. The Company expects to report the results of the follow-up study in the next 2 weeks once final analysis of the data is completed.
